Skip to main content

Table 2 Univariate and multivariable analysis for biochemical recurrence-free survival in patients with high-risk prostate cancer who underwent radical prostatectomy with and without neoadjuvant treatment

From: Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer

Variables Univariate Multivariable
HR 95%CI P value HR 95%CI P value
Age 0.92 0.85–1.00 0.035    
Completion of NAC (medify vs complete) 0.84 0.35–2.02 0.689    
Baseline PSA level (continuous) 1.02 1.01–1.04 0.006 1.03 1.01–1.05 0.010
Gleason score at diagnosis (≥8 vs ≤7) 2.00 0.74–5.38 0.169    
Extended lymph node dissection (yes vs no) 1.51 0.60–3.81 0.382    
pT (≥3 vs ≤2) 4.40 1.91–10.13 < 0.001 1.13 0.30–4.22 0.854
pN (+ or 0) 4.60 1.90–11.11 0.001 3.94 1.06–14.62 0.040
Resective margin (positive or negative) 2.00 0.46–8.67 0.355    
Nuclear expression of AR in epitherial cell (High vs low) 3.00 1.22–7.35 0.017 0.98 0.32–3.02 0.971
Nuclear expression of GR in epitherial cell (High vs low) 1.82 0.79–4.18 0.161    
Nuclear expression of ERα in stromal cell (High vs low) 2.37 0.84–6.64 0.101    
Nuclear expression of PR in stromal cell (High vs low) 0.45 0.20–1.02 0.054    
Nuclear expression of YAP in epitherial cell (High vs low) 2.44 1.08–5.55 0.033 3.32 1.32–8.37 0.011
Cytoplasmic expression of MOB4A in epitherial cell (High vs low) 1.73 0.77–3.91 0.190    
  1. NAC neoadjuvant treatment, PSA prostate specific antigen, AR androgen receptor, GR glucocorticoid receptor, ER estrogen receptor, PR progesterone receptor